List of Tables
TABLE 1. CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY 5-HT3 RECEPTOR ANTAGONISTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY GRANISETRON, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ONDANSETRON, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY PALONOSETRON, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY RAMOSETRON, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY 5-HT3 RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DEXAMETHASONE, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY METHYLPREDNISOLONE, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DOPAMINE RECEPTOR ANTAGONISTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY METOCLOPRAMIDE, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY PROCHLORPERAZINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DOPAMINE RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY NK1 RECEPTOR ANTAGONISTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY APREPITANT, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY FOSAPREPITANT, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY NK1 RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DUAL REGIMEN, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY 5-HT3 AND NK1, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY 5-HT3 AND STEROID, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY NK1 AND STEROID, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DUAL REGIMEN, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY TRIPLE REGIMEN, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY EMETIC RISK, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY HIGH, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY LOW, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY MINIMAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY MODERATE, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 55. AMERICAS CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY 5-HT3 RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 56. AMERICAS CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 57. AMERICAS CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DOPAMINE RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 58. AMERICAS CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY NK1 RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 59. AMERICAS CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 60. AMERICAS CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 61. AMERICAS CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 62. AMERICAS CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DUAL REGIMEN, 2018-2030 (USD MILLION)
TABLE 63. AMERICAS CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 64. AMERICAS CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 65. AMERICAS CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY EMETIC RISK, 2018-2030 (USD MILLION)
TABLE 66. AMERICAS CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 67. AMERICAS CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 68. UNITED STATES CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 69. UNITED STATES CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY 5-HT3 RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 70. UNITED STATES CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 71. UNITED STATES CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DOPAMINE RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 72. UNITED STATES CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY NK1 RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 73. UNITED STATES CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 74. UNITED STATES CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 75. UNITED STATES CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 76. UNITED STATES CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DUAL REGIMEN, 2018-2030 (USD MILLION)
TABLE 77. UNITED STATES CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 78. UNITED STATES CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 79. UNITED STATES CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY EMETIC RISK, 2018-2030 (USD MILLION)
TABLE 80. UNITED STATES CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 81. UNITED STATES CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 82. CANADA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 83. CANADA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY 5-HT3 RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 84. CANADA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 85. CANADA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DOPAMINE RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 86. CANADA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY NK1 RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 87. CANADA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 88. CANADA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 89. CANADA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 90. CANADA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DUAL REGIMEN, 2018-2030 (USD MILLION)
TABLE 91. CANADA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 92. CANADA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 93. CANADA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY EMETIC RISK, 2018-2030 (USD MILLION)
TABLE 94. CANADA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 95. MEXICO CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 96. MEXICO CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY 5-HT3 RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 97. MEXICO CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 98. MEXICO CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DOPAMINE RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 99. MEXICO CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY NK1 RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 100. MEXICO CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 101. MEXICO CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 102. MEXICO CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 103. MEXICO CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DUAL REGIMEN, 2018-2030 (USD MILLION)
TABLE 104. MEXICO CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 105. MEXICO CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 106. MEXICO CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY EMETIC RISK, 2018-2030 (USD MILLION)
TABLE 107. MEXICO CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 108. BRAZIL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 109. BRAZIL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY 5-HT3 RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 110. BRAZIL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 111. BRAZIL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DOPAMINE RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 112. BRAZIL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY NK1 RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 113. BRAZIL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 114. BRAZIL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 115. BRAZIL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 116. BRAZIL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DUAL REGIMEN, 2018-2030 (USD MILLION)
TABLE 117. BRAZIL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 118. BRAZIL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 119. BRAZIL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY EMETIC RISK, 2018-2030 (USD MILLION)
TABLE 120. BRAZIL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 121. ARGENTINA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 122. ARGENTINA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY 5-HT3 RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 123. ARGENTINA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 124. ARGENTINA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DOPAMINE RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 125. ARGENTINA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY NK1 RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 126. ARGENTINA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 127. ARGENTINA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 128. ARGENTINA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 129. ARGENTINA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DUAL REGIMEN, 2018-2030 (USD MILLION)
TABLE 130. ARGENTINA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 131. ARGENTINA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 132. ARGENTINA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY EMETIC RISK, 2018-2030 (USD MILLION)
TABLE 133. ARGENTINA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 134. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 135. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY 5-HT3 RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 136. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 137. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DOPAMINE RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 138. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY NK1 RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 139. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 140. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 141. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 142. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DUAL REGIMEN, 2018-2030 (USD MILLION)
TABLE 143. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 144. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 145. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY EMETIC RISK, 2018-2030 (USD MILLION)
TABLE 146. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 147. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 148. UNITED KINGDOM CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 149. UNITED KINGDOM CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY 5-HT3 RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 150. UNITED KINGDOM CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 151. UNITED KINGDOM CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DOPAMINE RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 152. UNITED KINGDOM CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY NK1 RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 153. UNITED KINGDOM CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 154. UNITED KINGDOM CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 155. UNITED KINGDOM CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 156. UNITED KINGDOM CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DUAL REGIMEN, 2018-2030 (USD MILLION)
TABLE 157. UNITED KINGDOM CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 158. UNITED KINGDOM CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 159. UNITED KINGDOM CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY EMETIC RISK, 2018-2030 (USD MILLION)
TABLE 160. UNITED KINGDOM CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 161. GERMANY CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 162. GERMANY CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY 5-HT3 RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 163. GERMANY CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 164. GERMANY CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DOPAMINE RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 165. GERMANY CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY NK1 RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 166. GERMANY CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 167. GERMANY CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 168. GERMANY CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 169. GERMANY CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DUAL REGIMEN, 2018-2030 (USD MILLION)
TABLE 170. GERMANY CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 171. GERMANY CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 172. GERMANY CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY EMETIC RISK, 2018-2030 (USD MILLION)
TABLE 173. GERMANY CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 174. FRANCE CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 175. FRANCE CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY 5-HT3 RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 176. FRANCE CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 177. FRANCE CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DOPAMINE RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 178. FRANCE CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY NK1 RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 179. FRANCE CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 180. FRANCE CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 181. FRANCE CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 182. FRANCE CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DUAL REGIMEN, 2018-2030 (USD MILLION)
TABLE 183. FRANCE CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 184. FRANCE CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 185. FRANCE CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY EMETIC RISK, 2018-2030 (USD MILLION)
TABLE 186. FRANCE CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 187. RUSSIA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 188. RUSSIA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY 5-HT3 RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 189. RUSSIA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 190. RUSSIA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DOPAMINE RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 191. RUSSIA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY NK1 RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 192. RUSSIA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 193. RUSSIA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 194. RUSSIA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 195. RUSSIA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DUAL REGIMEN, 2018-2030 (USD MILLION)
TABLE 196. RUSSIA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 197. RUSSIA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 198. RUSSIA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY EMETIC RISK, 2018-2030 (USD MILLION)
TABLE 199. RUSSIA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 200. ITALY CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 201. ITALY CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY 5-HT3 RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 202. ITALY CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 203. ITALY CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DOPAMINE RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 204. ITALY CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY NK1 RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 205. ITALY CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 206. ITALY CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 207. ITALY CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 208. ITALY CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DUAL REGIMEN, 2018-2030 (USD MILLION)
TABLE 209. ITALY CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 210. ITALY CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 211. ITALY CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY EMETIC RISK, 2018-2030 (USD MILLION)
TABLE 212. ITALY CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 213. SPAIN CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 214. SPAIN CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY 5-HT3 RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 215. SPAIN CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 216. SPAIN CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DOPAMINE RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 217. SPAIN CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY NK1 RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 218. SPAIN CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 219. SPAIN CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 220. SPAIN CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 221. SPAIN CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DUAL REGIMEN, 2018-2030 (USD MILLION)
TABLE 222. SPAIN CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 223. SPAIN CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 224. SPAIN CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY EMETIC RISK, 2018-2030 (USD MILLION)
TABLE 225. SPAIN CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 226. UNITED ARAB EMIRATES CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 227. UNITED ARAB EMIRATES CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY 5-HT3 RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 228. UNITED ARAB EMIRATES CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 229. UNITED ARAB EMIRATES CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DOPAMINE RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 230. UNITED ARAB EMIRATES CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY NK1 RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 231. UNITED ARAB EMIRATES CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 232. UNITED ARAB EMIRATES CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 233. UNITED ARAB EMIRATES CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 234. UNITED ARAB EMIRATES CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DUAL REGIMEN, 2018-2030 (USD MILLION)
TABLE 235. UNITED ARAB EMIRATES CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 236. UNITED ARAB EMIRATES CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 237. UNITED ARAB EMIRATES CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY EMETIC RISK, 2018-2030 (USD MILLION)
TABLE 238. UNITED ARAB EMIRATES CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 239. SAUDI ARABIA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 240. SAUDI ARABIA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY 5-HT3 RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 241. SAUDI ARABIA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 242. SAUDI ARABIA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DOPAMINE RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 243. SAUDI ARABIA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY NK1 RECEPTOR ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 244. SAUDI ARABIA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 245. SAUDI ARABIA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 246. SAUDI ARABIA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 247. SAUDI ARABIA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DUAL REGIMEN, 2018-2030 (USD MILLION)
TABLE 248. SAUDI ARABIA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 249. SAUDI ARABIA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 250. SAUDI ARABIA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY EMETIC RISK, 2018-2030 (USD MILLION)
TABLE 251. SAUDI ARABIA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 252. SOUTH AFRICA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 253. SOUTH AFRICA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY 5-HT3 RECEPTOR ANTAGONISTS, 2018-2030 (USD MILL